BRA
VRTX icon

Blue Rock Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Blue Rock Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,142
Closed -$1.94M – 90
2020
Q3 		$1.94M Buy
+7,142
New +$1.97M 1.68% 9

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Blue Rock Advisors's VRTX Position: Q4 2020 in Review

Blue Rock Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 7,142 shares — an estimated $1.94M sold.

Blue Rock Advisors first reported a position in VRTX in Q3 2020 and held it in 1 quarter. The position peaked at $1.94M in Q3 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Blue Rock Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Blue Rock Advisors sold 7,142 Vertex Pharmaceuticals shares in Q4 2020, an estimated $1.94M.
  • Blue Rock Advisors first reported a position in Vertex Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Blue Rock Advisors's Vertex Pharmaceuticals position peaked at $1.94M in Q3 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Blue Rock Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.